White Label Google Ads Management for Fertility Centers

This page is written for agency owners and consultants with fertility clinic clients rather than for clinics. If you fulfil in this vertical you will have noticed it behaves unlike the rest of your healthcare book, and the reason is a second rulebook most agencies never encounter. Alongside the platform restrictions, which treat reproductive health as a sensitive category and remove remarketing and personalized targeting, sits the Society for Assisted Reproductive Technology. SART maintains advertising guidelines, operates an Advertising Committee that reviews member clinics' websites and advertising materials, and can revoke membership for non-compliance, with membership status appearing in the CDC's federally mandated annual report. Reporting on the field describes programmes being instructed to modify their advertising practices. That means a campaign built without reference to those guidelines can create a professional problem for your client that never surfaces in a platform disapproval queue, and that you will be asked about.

1The Rulebook Most Agencies Miss

Four features make fertility accounts different from a general healthcare book.

• A professional body reviews the advertising. SART's Advertising Committee examines member clinics' websites and materials, and reporting describes membership revocation as a real consequence.
• Membership status is publicly reported. It appears in the CDC's federally mandated annual report, so a problem is visible to patients and referring physicians.
• Remarketing is unavailable. Reproductive health is a sensitive category, so the standard answer to a decision cycle running months does not exist.
• Measurement has to reach unusually far down. Reported figures describe several consultations per started cycle, so lead-level reporting describes almost nothing.

The first two are what should change how you staff and price these accounts. Producing marketing that puts a client's SART standing in question is a materially worse outcome than a disapproved ad, and it is not a risk most agency processes are built to catch.

2Success Rate Requests and How We Handle Them

This is the request that arrives on every fertility account, and it is where an agency either adds value or creates exposure.

A clinic will want to lead with its success rates, frequently because a competitor is doing so. The guidelines as described in published research direct clinics to present their Clinic Summary Report as the primary display, to accompany any supplemental figures with live birth rate per cycle, per egg retrieval, and per embryo transfer across recognised age categories, to carry a disclaimer noting comparisons may not be meaningful, and to avoid claims of superiority over other centres.

None of that fits in an ad. Our position is that outcome data does not appear in ad copy, that landing pages carrying success rates are built to the guideline structure, and that the client's medical director approves the presentation rather than their marketing lead or us.

When a client points at a competitor's ad, the useful response is not refusal. It is explaining what the guidelines contemplate, noting that published research has found most clinics displaying rates were missing required elements, and offering the alternative, which is a properly built outcome page that the ad drives to. Clinicians generally find this persuasive because it is their own field's standard rather than an agency preference.

3What We Decline to Run

Published in advance so fit can be assessed before a contract rather than during a disagreement.

1. Success rate claims in ad copy. The required qualifications cannot travel with the claim into an ad.
2. Comparative or superiority claims about other clinics. Comparison marketing falls outside the guidelines.
3. Baby and newborn imagery as the primary creative device. It operates as an implied outcome promise and reaches patients for whom treatment failed.
4. Remarketing or audience construction on reproductive health characteristics. Including indirect technical arrangements achieving the same effect.
5. Urgency or age-pressure framing. Manipulative and clinically simplistic.
6. Patient stories presented as evidence of clinic performance. Requiring documented authorisation at minimum and inappropriate as proof regardless.
7. Undisclosed paid partnership content. ASRM commentary has flagged fertility influencer compensation as requiring disclosure.

Every item corresponds to something the field's own professional guidance or a platform policy addresses. This is not agency caution, it is the operating standard of the specialty.

4What We Run and What You Keep

We own execution, you own the client.

The medical director row matters and is not negotiable. Neither an agency nor a marketing manager is the right approver for outcome data in a field where a professional committee reviews it, and insisting on that protects your client and your relationship with them.

5Reporting to Consultations and Cycles

Standard advertising reporting is close to useless here, and presenting it to a fertility client will eventually cost you the account.

Reported figures describe two to four consultations per started cycle and all-in acquisition costs of roughly $200 to $600 per IVF start through paid channels. Against per-patient revenue reported at $40,000 to $80,000 across a treatment relationship, the client's real question is never what a click cost.

Our reporting runs enquiries, consultations booked, consultations attended, and cycles started where the practice can supply the data, split by channel and service line, with branded separated from non-branded since branded performs the recovery role remarketing would otherwise play.

We add quarterly cohort views, tracking patients acquired in a period forward through treatment. In a category with this long a cycle, cohort analysis is the only way to distinguish a channel producing consultations from a channel producing patients, and it is the analysis that makes you look like a strategic partner rather than a media vendor.

6Privacy Boundaries and Measurement Limits

Reproductive health data is among the most sensitive that exists, and this is an area where we will tell you no on your client's behalf.

Third-party tags on pages where patients book, complete intake, or access records create a data flow requiring review, and the decision belongs with the clinic's privacy officer or counsel. We raise it in onboarding rather than discovering it in an audit, and we design measurement around whatever answer the clinic gets.

The same applies to patient list uploads for audience building. Uploading fertility patient data to an advertising platform is not a routine marketing action, and where the clinic's review says no, the campaign is built without it.

Expect lower resolution than in other verticals as a result. The metrics that matter most come from the clinic's own systems anyway, and a partner who accepts that boundary is protecting your client rather than limiting them.

7When the Client Cannot Take More Patients

Fertility capacity is unusually rigid, constrained by physician consultation slots, embryology laboratory throughput, and procedure scheduling. Laboratory capacity in particular cannot be expanded quickly.

We will tell you when a budget increase is not the right recommendation, because generating more cycle starts than a laboratory can safely handle is a clinical risk rather than a growth outcome, and a practice with a six-week wait for a first consultation is losing patients regardless of how many enquiries arrive.

The productive redirects are improving consultation attendance and conversion from existing volume, developing referring physician relationships, working returning and storage patients, or shifting toward services with different capacity profiles such as evaluation and egg freezing.

Raising that conversation positions you as someone thinking about the practice rather than the account, which in a specialty this relationship-driven is worth more than the incremental spend would have been.

8How the Margin Works

Our fee starts at $300 per month per account, and you set client pricing. Partners in regulated specialties typically bill considerably above that given the review burden these accounts carry.

We do not require a term commitment or a minimum number of accounts. Beginning with a single account is particularly sensible here, since you will want to see how the guideline conversations land with a clinical client before moving more of your book.

Media budget is billed directly to the clinic. Given the professional and regulatory context, the practice should hold undisputed ownership of its advertising account and its full history.

What you are buying is a partner who has read the field's advertising guidelines and will apply them. What stays with you is the client relationship, your rate, and the advisory position.

9Who This Partnership Suits

It works well for healthcare marketing firms with fertility clients where the specialty is a small share of the book. For agencies serving hospital systems or multi-site groups where a fertility service line sits inside a broader relationship. For web and SEO firms whose clinic clients keep asking for paid search. And for consultants who want fulfilment that will not create professional exposure under their name.

It suits you less well if the client expects success rate advertising and you would rather not have that conversation, if you need someone to also own the client relationship, or if your model depends on marking up media spend.

If you are weighing it up, the most useful first step is a guideline audit of one existing client's site and campaigns. In this vertical that audit routinely surfaces findings more consequential than anything in the ad account, and knowing about them has value whether or not we work together.